HLS Therapeutics（HLS）株式概要
HLSセラピューティクス社は、精神疾患、中枢神経系、心血管系疾患の治療用医薬品をカナダ、米国、および国際的に買収、販売しているスペシャリティ・ファーマです。 詳細
HLS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
HLS Therapeutics Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | CA$4.11 |
| 52週高値 | CA$5.77 |
| 52週安値 | CA$4.00 |
| ベータ | 0.86 |
| 1ヶ月の変化 | -5.30% |
| 3ヶ月変化 | -11.61% |
| 1年変化 | -16.12% |
| 3年間の変化 | -33.17% |
| 5年間の変化 | -76.35% |
| IPOからの変化 | -64.54% |
最新ニュース
ナラティブ更新 • Jun 23
HLS: Future Upside Will Depend On Executing Reaffirmed 2026 Earnings Guidance
Analysts have adjusted their CA$5 price target on HLS Therapeutics in light of updated assumptions for revenue growth, profit margins, and future P/E. This reflects a refined view of the stock's potential value.
ナラティブ更新 • Jun 07
HLS: Future Execution Risks Will Restrain Benefits Of New Franchise And Hold Stance
Analysts have updated their view on HLS Therapeutics with a refined fair value of CA$4.49 per share. This is supported by refreshed assumptions on revenue growth, profit margins, discount rate and future P/E that align with recent Street price targets in the CA$4.45 to CA$5.00 range.ナラティブ更新 • May 24
HLS: Future Upside Will Depend On Delivering New 2026 Revenue Guidance
Analysts have modestly adjusted their CA$ price target on HLS Therapeutics, with models reflecting a fair value estimate holding close to CA$12.00, supported by recent Hold-rated coverage and slightly lower Street targets around CA$4.45 to CA$5.00. Analyst Commentary Recent Street research on HLS Therapeutics has centered on Hold ratings paired with price targets in the CA$4.45 to CA$5.00 range.Recent updates
ナラティブ更新 • Jun 23
HLS: Future Upside Will Depend On Executing Reaffirmed 2026 Earnings Guidance
Analysts have adjusted their CA$5 price target on HLS Therapeutics in light of updated assumptions for revenue growth, profit margins, and future P/E. This reflects a refined view of the stock's potential value.ナラティブ更新 • Jun 07
HLS: Future Execution Risks Will Restrain Benefits Of New Franchise And Hold Stance
Analysts have updated their view on HLS Therapeutics with a refined fair value of CA$4.49 per share. This is supported by refreshed assumptions on revenue growth, profit margins, discount rate and future P/E that align with recent Street price targets in the CA$4.45 to CA$5.00 range.ナラティブ更新 • May 24
HLS: Future Upside Will Depend On Delivering New 2026 Revenue Guidance
Analysts have modestly adjusted their CA$ price target on HLS Therapeutics, with models reflecting a fair value estimate holding close to CA$12.00, supported by recent Hold-rated coverage and slightly lower Street targets around CA$4.45 to CA$5.00. Analyst Commentary Recent Street research on HLS Therapeutics has centered on Hold ratings paired with price targets in the CA$4.45 to CA$5.00 range.ナラティブ更新 • May 04
HLS: Future Upside Will Depend On Executing Refined Earnings Outlook
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on the company that feed into revised assumptions regarding growth, margins and future P/E. Analyst Commentary Recent research updates on HLS Therapeutics show price targets aligning at CA$4.45, with ratings maintained rather than shifted to more negative stances.ナラティブ更新 • Apr 18
HLS: Future Execution Risks Will Temper Benefits Of New Cholesterol Franchise
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on its growth profile and profitability. Analyst Commentary Bearish analysts are signaling a more cautious stance on HLS Therapeutics after the revised CA$4.45 price target.ナラティブ更新 • Apr 02
HLS: Future Execution Risks Will Offset New Product And Margin Assumptions
Analysts have trimmed their price target on HLS Therapeutics to CA$4.45 from CA$4.75, reflecting updated views on the company’s revenue growth potential, profit margin outlook, and a higher assumed future P/E multiple. Analyst Commentary Bearish analysts have reacted to recent developments by trimming their price target on HLS Therapeutics to CA$4.45 from CA$4.75, while maintaining a Hold stance.ナラティブ更新 • Mar 18
HLS: Future Share Performance Will Rely On Execution Against Updated Outlook
The analyst price target for HLS Therapeutics has been reduced by CA$0.30 to CA$4.45. Analysts cited updated assumptions around growth, profitability and valuation multiples as key drivers for the change.ナラティブ更新 • Mar 03
HLS: Fair Outlook Will Balance Revised Profitability Assumptions And Execution Risks
Analysts have trimmed their price target on HLS Therapeutics to CA$4.72 from CA$4.76, reflecting updated assumptions around discount rates, revenue growth, profit margins, and a slightly lower future P/E multiple. Valuation Changes Fair Value: CA$ fair value estimate adjusted slightly from CA$4.76 to CA$4.72.ナラティブ更新 • Feb 17
HLS: Improved Profitability Outlook Will Support Stronger Future Share Performance
Analysts now see fair value for HLS Therapeutics at about CA$11.59, slightly below the prior CA$11.79. This reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations.ナラティブ更新 • Feb 03
HLS: Higher Profitability Outlook Will Support Upgraded Future Share Performance
Analysts have nudged their price target on HLS Therapeutics higher to C$7 from C$6, pointing to updated assumptions on revenue growth, profit margins and future P/E levels that support a slightly revised outlook for the shares. Analyst Commentary Recent Street research reflects a slightly more optimistic tone around HLS Therapeutics, with bullish analysts adjusting their models to support a higher valuation anchor for the shares.ナラティブ更新 • Jan 20
HLS: Higher Profitability Outlook Will Drive Stronger Future Share Performance
Analysts have raised their price target on HLS Therapeutics to C$7 from C$6, reflecting updated views on fair value, growth expectations, profitability, and future P/E assumptions. Analyst Commentary Recent Street research points to a more constructive view on HLS Therapeutics, with bullish analysts revisiting their assumptions on fair value, growth potential, and what they are willing to pay on a P/E basis.ナラティブ更新 • Jan 06
HLS: Higher Rating Outlook Will Balance Execution Risks And Near Term Guidance
Analysts lifted their price target for HLS Therapeutics to C$7 from C$6, citing updated assumptions around fair value, discount rate, revenue growth, profit margins and a lower future P/E multiple in their models. Analyst Commentary Even with the price target now set at C$7, some research commentary still reads as cautious.ナラティブ更新 • Dec 14
HLS: Higher Projected Earnings Will Support Stronger Future Share Performance
Analysts have raised their price target on HLS Therapeutics by C$1 to C$7, reflecting higher projected fair value, faster expected revenue growth, and improved profit margin assumptions, despite a slightly higher discount rate and lower future P/E multiple. Analyst Commentary Bullish analysts highlight that the higher price target reflects growing confidence in HLS Therapeutics execution and earnings trajectory, even after factoring in a modestly higher risk profile.
ナラティブ更新 • Nov 19
HLS: Ongoing Share Buybacks And Debt Reduction Will Drive Positive Momentum
The analyst price target for HLS Therapeutics has increased from C$6 to C$7. This reflects analysts’ confidence in the company’s improving financial performance and ongoing strategic initiatives.分析記事 • Nov 16
HLS Therapeutics Inc. (TSE:HLS) Just Reported, And Analysts Assigned A CA$6.80 Price Target
The analysts might have been a bit too bullish on HLS Therapeutics Inc. ( TSE:HLS ), given that the company fell short...ナラティブ更新 • Sep 25
Canadian Regulatory Approvals Will Foster A Vibrant Cardiovascular Market
Analysts have raised their price target for HLS Therapeutics to CA$7.41, citing positive impacts from share buybacks, debt reduction, and an expanding product portfolio, alongside signs of adjusted EBITDA recovery and improved operational performance. Analyst Commentary Share buybacks and debt reduction are viewed positively for capital allocation and balance sheet strength.
新しいナラティブ • Apr 07
Vascepa Sales In Canada And Cost Cuts Will Transform Prospects
Significant revenue growth is expected from Vascepa in Canada, driven by increased prescriptions and stabilizing payer mix, positively impacting revenue.分析記事 • Oct 26
Are Investors Undervaluing HLS Therapeutics Inc. (TSE:HLS) By 45%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, HLS Therapeutics fair value estimate is CA$6.42 Current share...分析記事 • Sep 28
Pinning Down HLS Therapeutics Inc.'s (TSE:HLS) P/S Is Difficult Right Now
It's not a stretch to say that HLS Therapeutics Inc.'s ( TSE:HLS ) price-to-sales (or "P/S") ratio of 1.5x right now...分析記事 • May 12
Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results
It's shaping up to be a tough period for HLS Therapeutics Inc. ( TSE:HLS ), which a week ago released some...分析記事 • Apr 14
After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
The HLS Therapeutics Inc. ( TSE:HLS ) share price has done very well over the last month, posting an excellent gain of...分析記事 • Apr 06
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Nov 16
Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Market forces rained on the parade of HLS Therapeutics Inc. ( TSE:HLS ) shareholders today, when the analysts...分析記事 • Sep 13
Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • May 05
Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Apr 05
HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
The board of HLS Therapeutics Inc. ( TSE:HLS ) has announced that it will pay a dividend on the 15th of June, with...分析記事 • Mar 20
HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
The board of HLS Therapeutics Inc. ( TSE:HLS ) has announced that it will pay a dividend on the 15th of June, with...株主還元
| HLS | CA Pharmaceuticals | CA 市場 | |
|---|---|---|---|
| 7D | -4.6% | -1.3% | -0.1% |
| 1Y | -16.1% | 39.8% | 28.4% |
業界別リターン: HLS過去 1 年間で39.8 % の収益を上げたCanadian Pharmaceuticals業界を下回りました。
リターン対市場: HLSは、過去 1 年間で28.4 % のリターンを上げたCanadian市場を下回りました。
価格変動
| HLS volatility | |
|---|---|
| HLS Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in CA Market | 16.6% |
| 10% least volatile stocks in CA Market | 3.6% |
安定した株価: HLS 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: HLSの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| n/a | 85 | Craig Millian | www.hlstherapeutics.com |
スペシャリティファーマであるHLS Therapeutics Inc.は、精神疾患、中枢神経系、心血管疾患の治療用医薬品をカナダ、米国、および国際的に買収、販売している。同社の主力製品には、治療抵抗性統合失調症の症状管理を目的とした非定型抗精神病薬クロザリルや、心血管系疾患を対象としたイコサペントエチルカプセルのバセパなどがある。また、MyCare精神科用ラボアッセイや、患者の薬物濃度を測定するポイントオブケア機器MyCare Insiteも販売している。HLSセラピューティクス・インクはカナダのエトビコークに本社を置いている。
HLS Therapeutics Inc. 基礎のまとめ
| HLS 基礎統計学 | |
|---|---|
| 時価総額 | CA$128.54m |
| 収益（TTM） | -CA$14.42m |
| 売上高(TTM) | CA$78.10m |
1.6x
P/Sレシオ-8.9x
PER（株価収益率HLS は割高か？
公正価値と評価分析を参照収益と収入
| HLS 損益計算書（TTM） | |
|---|---|
| 収益 | US$55.74m |
| 売上原価 | US$16.15m |
| 売上総利益 | US$39.59m |
| その他の費用 | US$49.89m |
| 収益 | -US$10.29m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.33 |
| グロス・マージン | 71.03% |
| 純利益率 | -18.46% |
| 有利子負債／自己資本比率 | 73.5% |
HLS の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/19 15:24 |
| 終値 | 2026/07/17 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
HLS Therapeutics Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4
| アナリスト | 機関 |
|---|---|
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Michael Freeman | Raymond James Ltd. |